Baricitinib Effects on Procoagulant State in Rheumatoid Arthritis

Sponsor
Tanta University
Study ID
NCT07357649
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Baricitinib — DRUG
    Oral baricitinib administered in combination with methotrexate according to standard clinical practice

Study Details

This prospective interventional study aims to evaluate the effects of baricitinib on disease activity, lipid profile, atherogenic index, and procoagulant biomarkers including monocyte-derived human tissue factor and D-dimer in patients with rheumatoid arthritis, compared with conventional therapy.

Key Dates

Start date
Jan 31, 2026
Status verified
Jan 2026
Primary completion
Apr 30, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
100 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Baricitinib
  • No Intervention: Conventional DMARD therapy

Primary Outcome Measure

Change in Monocyte-Derived Human Tissue Factor Level [ Time Frame: Baseline and 3 months ]

Related Studies